Presynaptic AMPA and kainate receptors increase the size of GABAergic terminals and enhance GABA release

Mónica L. Fiszman, F. Erdélyi, Gábor Szabó, Stefano Vicini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the developing cerebellum, NMDA receptors promote the maturation of axonal terminals of inhibitory interneurons. We compared the effects of AMPA/kainate receptor agonists in cultured cerebellar cells from GAD65-eGFP mice. Both AMPA and kainate augmented granule cell survival without affecting interneurons. The action of kainate was blocked by an AMPA but not by a NMDA receptor antagonist, suggesting AMPA receptor involvement. AMPA and kainate increased the size of the GABAergic terminals and the action of kainate was insensitive to NMDA blockers. Whole cell recordings in granule neurons revealed that chronic treatment for 5 days with kainate as well as NMDA decreased AMPA receptor expression while interneuronal kainate receptors were depressed by kainate treatment. Acute kainate application increased mIPSCs frequency in both granule neurons and interneurons and this effect was only partially blocked by an AMPA receptor antagonist. In contrast to what was reported for NMDA, chronic treatment with kainate induced a significant decrease of the basal mIPSCs frequency but increased the acute action of kainate on mIPSCs. Direct recordings from presynaptic GABAergic terminals suggest that AMPA and kainate receptors are present in developing GABAergic terminals and their activation affects the size of GABAergic terminals and spontaneous GABA release.

Original languageEnglish
Pages (from-to)1631-1640
Number of pages10
JournalNeuropharmacology
Volume52
Issue number8
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Presynaptic Receptors
Kainic Acid Receptors
AMPA Receptors
Kainic Acid
gamma-Aminobutyric Acid
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Interneurons
N-Methylaspartate
N-Methyl-D-Aspartate Receptors
Neurons
Presynaptic Terminals
Patch-Clamp Techniques
Cerebellum
Cultured Cells
Cell Survival

Keywords

  • Cerebellum
  • eGFP
  • Interneuron
  • Patch-clamp
  • Survival
  • Synapses

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Presynaptic AMPA and kainate receptors increase the size of GABAergic terminals and enhance GABA release. / Fiszman, Mónica L.; Erdélyi, F.; Szabó, Gábor; Vicini, Stefano.

In: Neuropharmacology, Vol. 52, No. 8, 06.2007, p. 1631-1640.

Research output: Contribution to journalArticle

Fiszman, Mónica L. ; Erdélyi, F. ; Szabó, Gábor ; Vicini, Stefano. / Presynaptic AMPA and kainate receptors increase the size of GABAergic terminals and enhance GABA release. In: Neuropharmacology. 2007 ; Vol. 52, No. 8. pp. 1631-1640.
@article{da85520a03a245a288d7a1125dcb74f6,
title = "Presynaptic AMPA and kainate receptors increase the size of GABAergic terminals and enhance GABA release",
abstract = "In the developing cerebellum, NMDA receptors promote the maturation of axonal terminals of inhibitory interneurons. We compared the effects of AMPA/kainate receptor agonists in cultured cerebellar cells from GAD65-eGFP mice. Both AMPA and kainate augmented granule cell survival without affecting interneurons. The action of kainate was blocked by an AMPA but not by a NMDA receptor antagonist, suggesting AMPA receptor involvement. AMPA and kainate increased the size of the GABAergic terminals and the action of kainate was insensitive to NMDA blockers. Whole cell recordings in granule neurons revealed that chronic treatment for 5 days with kainate as well as NMDA decreased AMPA receptor expression while interneuronal kainate receptors were depressed by kainate treatment. Acute kainate application increased mIPSCs frequency in both granule neurons and interneurons and this effect was only partially blocked by an AMPA receptor antagonist. In contrast to what was reported for NMDA, chronic treatment with kainate induced a significant decrease of the basal mIPSCs frequency but increased the acute action of kainate on mIPSCs. Direct recordings from presynaptic GABAergic terminals suggest that AMPA and kainate receptors are present in developing GABAergic terminals and their activation affects the size of GABAergic terminals and spontaneous GABA release.",
keywords = "Cerebellum, eGFP, Interneuron, Patch-clamp, Survival, Synapses",
author = "Fiszman, {M{\'o}nica L.} and F. Erd{\'e}lyi and G{\'a}bor Szab{\'o} and Stefano Vicini",
year = "2007",
month = "6",
doi = "10.1016/j.neuropharm.2007.03.010",
language = "English",
volume = "52",
pages = "1631--1640",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Presynaptic AMPA and kainate receptors increase the size of GABAergic terminals and enhance GABA release

AU - Fiszman, Mónica L.

AU - Erdélyi, F.

AU - Szabó, Gábor

AU - Vicini, Stefano

PY - 2007/6

Y1 - 2007/6

N2 - In the developing cerebellum, NMDA receptors promote the maturation of axonal terminals of inhibitory interneurons. We compared the effects of AMPA/kainate receptor agonists in cultured cerebellar cells from GAD65-eGFP mice. Both AMPA and kainate augmented granule cell survival without affecting interneurons. The action of kainate was blocked by an AMPA but not by a NMDA receptor antagonist, suggesting AMPA receptor involvement. AMPA and kainate increased the size of the GABAergic terminals and the action of kainate was insensitive to NMDA blockers. Whole cell recordings in granule neurons revealed that chronic treatment for 5 days with kainate as well as NMDA decreased AMPA receptor expression while interneuronal kainate receptors were depressed by kainate treatment. Acute kainate application increased mIPSCs frequency in both granule neurons and interneurons and this effect was only partially blocked by an AMPA receptor antagonist. In contrast to what was reported for NMDA, chronic treatment with kainate induced a significant decrease of the basal mIPSCs frequency but increased the acute action of kainate on mIPSCs. Direct recordings from presynaptic GABAergic terminals suggest that AMPA and kainate receptors are present in developing GABAergic terminals and their activation affects the size of GABAergic terminals and spontaneous GABA release.

AB - In the developing cerebellum, NMDA receptors promote the maturation of axonal terminals of inhibitory interneurons. We compared the effects of AMPA/kainate receptor agonists in cultured cerebellar cells from GAD65-eGFP mice. Both AMPA and kainate augmented granule cell survival without affecting interneurons. The action of kainate was blocked by an AMPA but not by a NMDA receptor antagonist, suggesting AMPA receptor involvement. AMPA and kainate increased the size of the GABAergic terminals and the action of kainate was insensitive to NMDA blockers. Whole cell recordings in granule neurons revealed that chronic treatment for 5 days with kainate as well as NMDA decreased AMPA receptor expression while interneuronal kainate receptors were depressed by kainate treatment. Acute kainate application increased mIPSCs frequency in both granule neurons and interneurons and this effect was only partially blocked by an AMPA receptor antagonist. In contrast to what was reported for NMDA, chronic treatment with kainate induced a significant decrease of the basal mIPSCs frequency but increased the acute action of kainate on mIPSCs. Direct recordings from presynaptic GABAergic terminals suggest that AMPA and kainate receptors are present in developing GABAergic terminals and their activation affects the size of GABAergic terminals and spontaneous GABA release.

KW - Cerebellum

KW - eGFP

KW - Interneuron

KW - Patch-clamp

KW - Survival

KW - Synapses

UR - http://www.scopus.com/inward/record.url?scp=34249749433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249749433&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2007.03.010

DO - 10.1016/j.neuropharm.2007.03.010

M3 - Article

C2 - 17493642

AN - SCOPUS:34249749433

VL - 52

SP - 1631

EP - 1640

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 8

ER -